Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01935973 · ClinicalTrials.gov registry record · Phase 1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 1 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 20
- Study locations
NCT01935973 is a Phase 1 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants, below the 338-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01935973, a Phase 1 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase I trial studies how well trametinib with or without GSK 2141795 (protein kinase B \[Akt\] inhibitor GSK2141795) works in treating patients with endometrial cancer that has come back (recurrent) or does not go to remission despite treatment (persistent). Trametinib and Akt inhibitor GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is a more effective treatment for endometrial cancer when given with or without ATK inhibitor GSK2141795.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Trametinib
- DRUG Uprosertib
Study Locations (20)
Ohio
- Case Western Reserve University - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Ohio State University Comprehensive Cancer Center - Columbus
- Hillcrest Hospital Cancer Center - Mayfield Heights
Connecticut
- Hartford Hospital - Hartford
- The Hospital of Central Connecticut - New Britain
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Georgia
- Augusta University Medical Center - Augusta
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-09-30 |
| Est. Completion | 2015-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01935973
The ClinicalTrials.gov registry entry for NCT01935973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 338-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (92% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01935973 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ohio, Connecticut, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01935973 about?
NCT01935973 is a clinical study titled "Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer". This randomized phase I trial studies how well trametinib with or without GSK 2141795 (protein kinase B \[Akt\] inhibitor GSK2141795) works in treating patients with endometrial cancer that has come back (recurrent) or does not go to remission despite treatment (persistent). Trametinib and Akt inhib...
What is the current status of trial NCT01935973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-09-30. Estimated completion is 2015-09-08.
What conditions does trial NCT01935973 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Undifferentiated Carcinoma.
What interventions are being tested in trial NCT01935973?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trametinib (DRUG), Uprosertib (DRUG).
Who is sponsoring clinical trial NCT01935973?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01935973 being conducted?
This trial has 20 study locations across Connecticut, Georgia, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Endometrial Adenocarcinoma
All registered trials for this condition
Endometrial Serous Adenocarcinoma
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.